View : 494 Download: 0
A randomised comparison of coronary stents according to short or prolonged durations of dual antiplatelet therapy in patients with acute coronary syndromes: a pre-specified analysis of the SMART-DATE trial
- Title
- A randomised comparison of coronary stents according to short or prolonged durations of dual antiplatelet therapy in patients with acute coronary syndromes: a pre-specified analysis of the SMART-DATE trial
- Authors
- Jang, Woo Jin; Lee, Jin Bae; Song, Young Bin; Choi, Ki Hong; Choi, Seung-Hyuk; Chun, Woo Jung; Oh, Ju Hyeon; Park, Ik Hyun; Doh, Joon-Hyung; Jeong, Jin-Ok; Park, Jong-Seon; Gwon, Hyeon-Cheol; Hahn, Joo-Yong
- Ewha Authors
- 장우진
- SCOPUS Author ID
- 장우진
- Issue Date
- 2021
- Journal Title
- EUROINTERVENTION
- ISSN
- 1774-024X
1969-6213
- Citation
- EUROINTERVENTION vol. 17, no. 5, pp. E411 - +
- Keywords
- ACS/NSTE-ACS; adjunctive pharmacotherapy; drug-eluting stent
- Publisher
- EUROPA EDITION
- Indexed
- SCIE; SCOPUS
- Document Type
- Article
- Abstract
- Background: Data on direct comparison between various drug-eluting stents with short duration dual anti platelet therapy (DAPT) are limited, especially in patients with acute coronary syndrome (ACS). Aims: We sought to compare biodegradable polymer biolimus-eluting stents (BP-BES) with durable polymer everolimus-eluting (DP-EES) and zotarolimus-eluting stents (DP-ZES) in patients with ACS according to different durations of DAPT. Methods: In the SMART-DATE trial, 2,712 patients with ACS underwent randomisation for allocation of DAPT (6 months [n=1,357] or 12 months or longer [n=1,355]) and type of stent (BP-BES [n=901]), DP-EES [n=904], or DP-ZES [n=907]). The primary endpoint was a composite of cardiac death, myocardial infarction, or stent thrombosis. Results: At 18 months, the primary endpoint was attained by 2.6% with BP-BES, 2.0% with DP-EES, and 2.1% with DP-ZES (HR 1.29, 95% CI: 0.70-2.39, p=0.42 for BP-BES vs DP-EES and HR 1.23, 95% CI: 0.67-2.26, p=0.50 for BP-BES vs DP-ZES). The treatment effect of BP-BES for the primary endpoint was consistent among patients receiving 6-month DAPT as well as those receiving 12-month or longer DAPT (BP-BES vs. DP-EES, p(interaction)=0.48 and BP-BES vs DP-ZES, p(interaction)=0.87). After excluding 179 patients (101 in the BP-BES group) who did not receive allocated DES, the per-protocol analysis showed similar results. Conclusions: The risk of a composite of cardiac death, myocardial infarction, or stent thrombosis was not significantly different between patients receiving BP-BES versus DP-EES or DP-ZES across a short or prolonged duration of DAPT after ACS.
- DOI
- 10.4244/EIJ-D-20-00556
- Appears in Collections:
- 의료원 > 의료원 > Journal papers
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML